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Abstract
Anaplastic thyroid cancer (ATC) is highly aggressive and has a poor therapeutic response
and leads to high mortality. It has been shown that activation of intracellular c-Jun N-ter‐
minal kinase (JNK) and c-ABL signaling pathways is one of the manifestations of the
highly resistant response to radiotherapy in ATC. Pharmacological inhibition of these
pathways in combination with radiotherapy is a potential treatment modality of ATC.
Keywords: Anaplastic thyroid cancer, JNK signaling pathway, c-ABL signaling pathway,
ionizing radiation, radioresistance, anthrapyrazolone, imatinib
1. Introduction
Thyroid malignant neoplasms are the most frequent endocrine tumor. They are classified into
two categories, differentiated carcinoma and undifferentiated carcinoma (anaplastic carcino‐
ma), based on the histological differentiation (Figure 1).
In the clinical course, differentiated thyroid carcinomas such as follicular cancer and papillary
cancer have relatively good prognosis. ATC is among the most aggressive solid malignancies
in human with a bad prognosis. In spite of active therapeutic and surgical treatment, ATC
provides mean survival time less than 8 months after diagnosis [1]. ATC is widely metastatic,
and it is highly resistant to regular therapeutic approaches such as surgical treatment,
chemotherapy, or radiotherapy. It was confirmed that thyroid cells are relatively resistant to
ionizing radiation (IR)-induced apoptosis [2, 3].
Currently, it is mainly approved that external beam radiotherapy of ATC should be combined
with different anti-tumor pharmacological agents to have better local control of the tumor [4].
The main goal of this combination is to reduce the clonogenic capacity and radioresistance of
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ATC cells with the aim of further improving the radiotherapy effect. It is conceivably that
molecular-targeted pharmacological agents can decrease cancer resistance to radiotherapy
through modulation of DNA repair, cell death pathway, intracellular signal transduction [5,
6], or senescence-like terminal growth arrest [7].
2. Radiation therapy
Radiation therapy, like most anti-tumor treatments, achieves its therapeutic effect by inducing
different types of cell death in tumors [8]. Over the past decade, our knowledge is rapidly
increasing regarding the discovery of various molecular pathways involved in determining
cell death after IR exposure [9]. The biological target of IR in the cell is DNA (Figure 2).
Double-strand breaks (DSBs) are the most destructive DNA alterations, which, if left unre‐
paired, may have serious consequences for cell survival, as they lead to genomic instability,
chromosome aberrations, or cell death. DSBs are irreparable and more responsible than the
single-strand DNA breaks for most of cell death in tumor as well as surrounding normal cells.
Cells respond to DNA damage by activating complex processes at the level of molecules and
genes to detect and repair DNA alterations. The formation of DSBs activated phosphorylation
of H2AX (the subtype of histone H2A). The phosphorylated form of H2AX is called γ-H2AX
[10]. Phosphorylation of H2AX plays a key role in DNA reparation, and it is necessary for the
assembly of DNA repair molecules at the sites containing damaged chromatin as well as for
activation of checkpoint proteins, which arrest the cell cycle progression [11]. The evaluation
of γ-H2AX levels may allow not only to control the efficiency of anti-tumor therapy but also
to predict cancer cell sensitivity to DNA-damaging anti-tumor agents and toxicity of anti-
tumor treatment toward normal cells. It is possible to detect H2AX phosphorylation by specific
γ-H2AX antibody and thus to detect DNA damage and repair in situ in individual cells. The
presence of γ-H2AX in chromatin can be exposed shortly after induction of DSBs in the form
of discrete nuclear foci (Figure 3) [12]. The presence of γ-H2AX-containing nuclear foci can be
measured by microscopy, flow cytometry, and Western blotting of tissue/cell lysates [13].
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Figure 1. Thyroid malignant neoplasms histology: (a) follicular carcinoma; (b) papillary carcinoma; and 
(c) anaplastic carcinoma. Hematoxylin and eosin stain. Original magnification ×100. 
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Figure 1. Thyroid malignant neoplasms histology: (a) follicular carcinoma; (b) papillary carcinoma; and (c) anaplastic
carcinoma (courtesy of professor Masahiro Nakashima, Nagasaki University, Japan). Hematoxylin and eosin stain.
Original magnification ×100.
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Figure 3. IR induces γ-H2AX nuclear foci formation in ATC cell lines: (a) non-radiated; (b) in 24 hours after 10 Gy IR
treatment (EXS-300 X-irradiator, Toshiba, Tokyo, Japan; 200 kV, 15 mA, 0.83 Gy/min). Compared to alternative meth‐
ods of DNA damage assessment, the immunocytochemical approach is less cumbersome and offers much greater sen‐
sitivity. Fluorescent immunocytochemistry. Confocal fluorescent microscopy. Original magnification ×400.
The main goal of radiotherapy is to deprive tumor cells of their multiplication potential and
finally to destroy the cancer cells. After IR exposure, cell death may occur by one or more of
Figure 2. The biological target of IR in the cell is DNA. IR-induced DNA damage of cancer cells can lead to cell death.
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the following mechanisms: immediate or delayed apoptosis, mitotic-linked death (mitotic
catastrophe), autophagy, and terminal growth arrest (senescence) associated with necrosis
(Figure 4).
Figure 4. Mechanisms of cancer cell death triggered by IR.
Radiotherapy does not destroy cancer cells right away. It takes hours, days, or weeks of anti-
tumor therapy before cancer cells start to die after which cancer cells continue dying for weeks
to months after ending of radiotherapy. The efficiency of radiotherapy has much to gain by
understanding the cell death mechanisms that are induced in tumor cells following irradiation
(Table 1). Strategies to use specific pharmacological agents that can inhibit the activity of key
molecules in intracellular signaling pathways combined with IR might potentiate therapy and
enhance tumor cell death [14].
Types of cell death Definition and characteristics Associated changes Detection methods
Necrosis Cells visibly swell with
breakdown of cell membrane.
Typical nuclei with
vacuolization and
disintegrated cell organelles.
Sometimes not considered
genetically determined.
Drop of ATP levels.
ROS over-generation.
Early permeability to vital dyes.
Staining with propidium iodide.
Electron microscopy.
Apoptosis Programmed cell death.
Cells shrink with blebbing of
cell membranes.
Condensed chromatin and
DNA fragmentation.
Stimulated by cyclin D1
activation and by Myc.
Can be inhibited by loss of
wild-type p53.
Caspase activation.
Sub-G1 peak in flow cytometry.
Annexin-V staining.
Quantification of ∆Ψm.
Internucleosomal laddering.
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Types of cell death Definition and characteristics Associated changes Detection methods
Dissipation of mitochondrial
transmembrane potential
(∆Ψm).
Senescence Cells do not divide, although
they remain metabolically
active.
Large and flat cells with
increased granularity.
Stimulated by Ras mutations
and telomerase shortening.
Inhibited by the loss of wild-
type p53, p16, and p21WAF1.
Staining for β-galactosidase at
pH 6 (SA-β-Gal+).
Absence of DNA synthesis
(BrdU incorporation).
Autophagy Programmed cell death in which
the cell digests itself.
Formation of vacuoles in
cytoplasm.
Cell death is accompanied by
massive autophagic
vacuolization of cytoplasm
without condensation.
LC3-I to LC3-II conversion
(LC3, microtubule-associated
protein).
Immunoblotting with LC3-
specific antibodies.
Immunofluorescence
microscopy (LC3-GFP fusion
protein).
Mitotic catastrophe Cell death occurring during or
after a faulty mitosis.
Giant cells with two or more
nuclei and partially condensed
chromatin.
Can lead to necrosis or
apoptosis-like death (p53-
independent).
Stimulated by deficiencies in
proteins involved in G1 and G2
checkpoints and in mitotic
spindle assembly.
Can follow caspase-dependent
or caspase-independent
pathways.
Cells with two or more nuclei
detected by microscopy or laser
scanning cytometry.
Aberrant mitotic figures.
Accumulation in G2/M and
polyploidy.
Table 1. Anti-proliferative response and cell death pathways observed upon radiotherapy.
3. JNK signaling pathway
c-Jun N-terminal kinases (JNKs) are multifunctional kinases, also known as stress-activated
protein kinases be a part of superfamily of mitogen-activated protein kinases (MAPKs) that
are involved in many physiological and pathological processes (Figure 5). At first, the JNKs
were originally identified as ultraviolet-responsive protein kinases by their capacity to
phosphorylate the N-terminal of the transcription factor c-Jun and by their activation in
response to various stresses [15]. Initial research works have shown that JNKs can be triggered
by various stimuli including growth factors [16, 17], cytokines [18], and stress factors [19]. It
was demonstrated that IR with level of 10 Gy induced JNK activation with a maximum at 30
minutes and return to baseline at 12 hours after exposure in ATC cell lines [7].
Other observations have demonstrated the crucial role of JNK pathway in mediating apoptotic
signaling in many cell death paradigms [20]. JNK signal transduction pathway regulates the
cellular reaction to IR and activating radiation-induced apoptosis [21]. However, it was shown
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that JNK cascade, via the stimulation of c-Jun and ATF-2 transcription factors, may provide
DNA repair and cell survival (Figure 6) [22].
Figure 6. Role of JNK kinase in DNA repair after IR-induced extensive damage.
For that reason, it was proposed that JNK pathway inhibition could result in sensitization of
distinct types of tumor cells to DNA damage.
Figure 5. Various extracellular and intracellular stimuli can activate JNKs. Constant JNK activation influences tumouri‐
genesis by both transcription-independent and transcription-dependent mechanisms involved in cell transformation,
proliferation, survival, migration, suppression of cell death, and inflammatory processes in tumor.
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4. c-ABL tyrosine kinase signaling pathway
c-ABL is an ubiquitously expressed tyrosine kinase that involves in various cellular signaling
processes. The c-ABL is highly expressed in normal and cancer cells [23, 24]. c-ABL is frequently
overexpressed in ATC cell lines (Figure 7) and thyroid cancer tissue samples (Figure 8).
c-ABL is an ubiquitously expressed tyrosine kinase that involves in various cellular 
signaling processes. The c-ABL is highly expressed in normal and cancer cells [23, 24]. 
c-ABL is frequently overexpressed in ATC cell lines (Figure 7) and thyroid cancer 
tissue samples (Figure 8). 
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Figure 7. c-ABL expression in ATC cell lines: (a) FRO cell line and (b) ARO cell line. Fluorescent 
immunocytochemistry. Confocal fluorescent microscopy. Original magnification ×400. 
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Figure 8. The different expression pattern of c-ABL: (a) high level of expression of c-ABL in anaplastic 
thyroid carcinoma; (b) follicular carcinoma; and (c) goiter. Immunohistochemistry: antibodies used were 
anti-c-ABL. Original magnification ×200. 
Previous experiments indicated that c-ABL is involved in regulation of the cell cycle 
and the cellular genotoxic stress response pathways. It was demonstrated that the 
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try. Confocal fluorescent microscopy. Original magnification ×400.
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growth arrest was accompanied by the down-regulation of c-ABL phosphorylation and 
of cyclins A and B1 levels and by the up-regulation of the cell cycle inhibitor p21cip1. 
Also, it was presented that p21cip1 expression is associated with improved survival in 
Figure 8. The different expression pattern of c-ABL: (a) high level of expression of c-ABL in anaplastic thyroid carcino‐
ma; (b) follicular carcinoma; and (c) goiter. Immunohistochemistry: antibodies used were anti-c-ABL. Original magnifi‐
cation ×200 (a,b) and ×100 (c).
P evious experiments indicated that c-ABL is involved in regulation of the cell cycle and th
cellular genotoxic stress response pathways. It was demonstrated that the growth arrest was
accompanied by the down-regulation of c-ABL phosphorylation and of cyclins A and B1 levels
and by the up-regulation of the cell cycle inhibitor p21cip1. Also, it was presented that p21cip1
expression is associated with improved survival in patients after adjuvant radiotherapy [25].
The cellular reaction elicited by c-ABL depends upon its location in cells. Accumulation of c-
ABL in the cytoplasm results in cell survival and proliferation. By contrast, nuclear c-ABL
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becomes activated and induces apoptosis following genotoxic stress [26]. DNA damage caused
by IR and other DNA-damaging agents has been shown to result in activation of the c-ABL
(Figure 9) [27].
Figure 9. Nuclear targeting of c-ABL in response to DNA damage.
It was demonstrated that IR induces redistribution of c-ABL between nucleus and cytoplasm
in ATC cells (Figure 10) [28].
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Figure 10. IR induces redistribution of c-ABL between nucleus and cytoplasm in ATC cells. Translocation 
of c-ABL in FRO cells after IR treatment (EXS-300 X-irradiator, Toshiba, Tokyo, Japan; 200 kV, 15 mA, 
0.83 Gy/min): (a) non-radiated; (b) in 6 hours after 10 Gy IR treatment. Fluorescent 
immunocytochemistry. Confocal fluorescent microscopy. Original magnification ×400. 
Notably, nuclear targeting of c-ABL is required for the induction of apoptosis in 
Figure 10. IR induces redistribution of c-ABL between nucleus and cytoplasm in ATC cells. Translocation of c-ABL in
FRO cells after IR treatment (EXS-300 X-irradiator, Toshiba, Tokyo, Japan; 200 kV, 15 mA, 0.83 Gy/min): (a) non-radiat‐
ed; (b) in 6 hours after 10 Gy IR treatment. Fluorescent immunocytochemistry. Confocal fluorescent microscopy. Origi‐
nal magnification ×400.
Notably, nuclear t rgeting of c-ABL is required fo  the induction of apoptosis in response to
DNA damage. Overexpression of c-ABL activates cell cycle arrest in G1, which requires kinase
activity and nuclear localizing signals and depends on the wild-type p53 tumor suppressor
(Figure 10). In addition, c-ABL binds p53 and enhances the DNA binding and transcripti nal
activity of p53 [29, 30].
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Previous studies have revealed that loss of wild-type p53 function by mutation of the gene can
lead differentiated thyroid cancer to anaplastic change [31, 32]. ATC is harbor mutations of
p53 in 80–90% of cases and characterized by aggressive course of disease. It was previously
demonstrated that thyroid cancer cells with p53 mutation are relatively resistant to IR-induced
apoptosis [33]. Relationships between c-ABL and p53 revealed dependence of p53-deficient
cells from c-ABL for enhanced proliferation, suggesting that pharmacologic inhibition of c-
ABL may have therapeutic value in the p53-deficient cancer cells [34]. Hence, pharmacological
inhibition of c-ABL kinase activity can modify the response of ATC cells to IR and could be a
promising treatment modality.
5. Senescence-like terminal growth arrest
Senescence is a physiological process of changes in cell metabolism associated with a series
of  inductive,  permissive,  and restrictive  communications  that  limit  the  cell  proliferative
capacity. Senescent cells are viable but non-dividing, stop to synthesize DNA, and become
enlarged and flattened with an increased granularity. Recent data show that senescence may
act  as  an  acute,  drug-  or  IR-induced  growth  arrest  program  in  numerous  stromal  and
epithelial  tumors  [35].  It  was  found  that  IR  induces  senescence-like  phenotype  (SLP)
associated with terminal growth arrest in ATC cell lines and also in primary thyrocyte line
in time- and dose-dependent manner [36].
The induction of SLP in thyroid cells can be identified by the following:
• Senescence-associated β-galactosidase (SA-β-Gal) staining method (Figure 11)
• Dual-flow cytometric analysis of cell proliferation and side light scatter using vital staining
with PKH-2 dye
• Double labeling technique for SA-β-Gal and 5-bromo-2′-deoxyuridine (BrdU)
• Staining for SA-β-Gal with consequent anti-thyroglobulin immunocytochemistry (Figure
12)
6. Anthrapyrazolone as a specific inhibitor of JNK signaling pathway
Anthrapyrazolone is a synthetic polyaromatic small molecule–specific inhibitor of c-JNK
signaling (Figure 13). Anthrapyrazolone acts as a reversible ATP-competitive inhibitor with
an identical capability toward JNK1, JNK2, and JNK3 with >20-fold selectivity versus various
tested kinases other than JNKs [37, 38].
In cell cultures, anthrapyrazolone shows dose-dependent inhibition of c-Jun phosphorylation
in the range of 5–50 µM [38]. It was demonstrated that combination of anthrapyrazolone and
IR treatment inhibited ATC cell growth [7]. Numerous SA-β-Gal–positive cells were markedly
increased when anthrapyrazolone was combined with IR (Figure 14).
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Figure 11. IR induces SLP associated with terminal growth arrest in human ATC cell lines: (a and c) non-irradiated; (b
and d) in 120 hours after 10 Gy IR treatment; ATC cells exhibited typical features of SLP. Induction of SA-β-Gal activity
(green) was mostly observed in large cells with increased granularity and flattened shape. SA-β-Gal staining method.
(a) and (b) Bright-field microscopy, original magnification ×200. (c) and (d) Confocal fluorescent microscopy; original
magnification ×400.
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Figure 12. IR-induced SA-β-Gal activity in the primary culture of human thyroid follicular cells: (a) thyroglobulin-posi‐
tive (brown) cells in primary culture, anti-thyroglobulin immunocytochemistry; (b) non-irradiated cells, double stain‐
ing for SA-β-Gal and thyroglobulin; and (c) in 120 hours after 10 Gy IR treatment, double staining for SA-β-Gal and
thyroglobulin. Original magnification ×200.
New Aspects in Molecular and Cellular Mechanisms of Human Carcinogenesis160
 
(a)  (b)  (c) 
Figure 14. Anthrapyrazolone potentiates SLP in irradiated ATC cells: (a) non-radiated; (b) treatment with 
anthrapyrazolone; and (c) in 120 hours after 10 Gy IR treatment combined with anthrapyrazolone. SA--
Gal staining method. Bright-field microscopy. Original magnification ×100. 
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damage in alkaline single cell gel electrophoresis (Comet assay), in ATC cells treated 
with anthrapyrazolone plus IR compared to IR alone, suggesting that inhibition of JNK 
signaling pathway retarded DNA repair [7]. 
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Figure 15. Anthrapyrazolone potentiates DNA damage in irradiated ATC cells: (a) non-radiated; (b) in 30 
minutes after 10 Gy IR treatment; and (c) in 5 minutes after 10 Gy IR treatment combined with 
anthrapyrazolone. UV-fluorescent microscope. 
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explore whether SLP induced by combination of anthrapyrazolone plus IR was 
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In this study, DNA repair rates after 10 Gy exposure were analyzed by Comet assay to 
explore whether SLP induced by combination of anthrapyrazolone plus IR was 
associated with accumulation of DNA damage. In this method, individual cells with 
damaged DNA embedded in agarose gels are subjected to an electric field and generate 
a characteristic pattern of DNA distribution forming a tail that, after staining with 
Figure 15. Anthrapyrazolone potentiates DNA damage in irradiated ATC cells: (a) non-radiated; (b) in 30 minutes after
10 Gy IR treatment; and (c) in 5 mi utes after 10 Gy IR treatment combined with anthrapyrazolone. UV-fluorescent
microscope.
Figure 13. Chemical structure of anthrapyrazolone.
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In this study, DNA repair rates after 10 Gy exposure were analyzed by Comet assay to explore
whether SLP induced by combination of anthrapyrazolone plus IR was associated with
accumulation of DNA damage. In this method, individual cells with damaged DNA embedded
in agarose gels are subjected to an electric field and generate a characteristic pattern of DNA
distribution forming a tail that, after staining with fluorescence dye, can be analyzed by
fluorescence microscopy. The extent and length of the comet’s tail correlates with the severity
of DNA damage [39].
Thus, one of the mechanisms that may contribute to the combination treatment effects is likely
the delay of DNA repair evoked by JNK pathway inhibition. Treatment with anthrapyrazolone
significantly delayed DNA rejoining after 10 Gy IR and increased the radiosensitivity of ATC
cells.
7. Imatinib as a selective inhibitor of c-ABL tyrosine kinase activity
Imatinib (also known as STI571 or Gleevec®) is a tyrosine kinase inhibitor with selectivity
toward BCR/ABL, c-ABL, platelet-derived growth factor receptor (PDGFR), and c-KIT (Figure
16) [40].
Figure 16. Chemical structure of imatinib.
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Figure 17. (a) ATC xenograft model (ATC cells were implanted s.c. into male athymic mice); (b) cell 
cycle inhibitor p21cip1 expression in non-radiated mouse ATC cells xenograft; (c) imatinib 10 µM 
combined with single dose of 10 Gy IR in 120 hours after treatment. Imatinib suppressed in vivo growth 
of ATC cells implanted into nude mice. (b and c) immunohistochemistry, antibodies used were anti-
p21cip1. Original magnification ×200. 
It was demonstrated that imatinib-induced S- and G2–M cell cycle arrest, leading to cell 
growth inhibition (Figure 18) [41]. 
 
(a)                                                                (b) 
Figure 18. To evaluate G2 arrest in ATC cells, changes in the percent mitotic cells should be determined: 
(a) in 120 hours after imatinib (10 µM) treatment and (b) in 120 hours after imatinib (10 µM) combined 
with single dose of 5 Gy IR treatment. 
The anti-tumor effect of imatinib is potentiated in adjunctive therapy with IR, not only 
due to inhibition of proliferative cell growth with transient cell cycle arrest and 
Figure 17. (a) ATC xenograft model (ATC cells were implanted s.c. into male athymic mice); (b) cell cycle inhibitor
p21cip1 expression in non-radiated ouse ATC cells xenograft; (c) imatinib 10 µM combined with single dose of 10 Gy
IR in 120 hours after treatment. Imatinib suppressed in vivo growth of ATC cells implanted into nude mice. (b and c)
immunohistochemistry, antibodies used were anti-p21cip1. Original magnification ×200.
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Imatinib impedes the growth of ATC cell lines in vitro through selective inhibition of c-ABL
tyrosine kinase activity [41]. In vivo, imatinib combined with IR promotes p21cip1 expression in
mice bearing ATC xenograft model (Figure 17).
It was demonstrated that imatinib-induced S- and G2–M cell cycle arrest, leading to cell growth
inhibition (Figure 18) [41].
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apoptosis but also due to the terminal growth arrest associated with SLP (Figure 19) 
[41]. 
 
(a)  (b)  (c) 
Figure 19. Phenotypic changes associated with SLP in ATC cells: (a) ATC cell line without treatment; (b) 
in 72 hours after imatinib (10 µM) treatment; (c) in 72 hours after imatinib (10 µM) treatment combined 
Figure 19. Phenotypic changes associated with SLP in ATC cells: (a) ATC cell line without treatment; (b) in 72 hours
after imatinib (10 µM) treatment; (c) in 72 hours after imatinib (10 µM) treatment combined with single dose of 5 Gy
IR. Enlarged and flattened morphology and increased granularity of ATC cells. Original magnification ×200.
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8. Conclusion
Intracellular JNK and c-ABL signaling pathways are essential components of ATC cell
proliferation and survival after radiation therapy. Hence, pharmacological inhibition of these
pathways in combination with radiotherapy may be a potential treatment modality of ATC.
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